Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [20]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17195-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#17195-1-AP, RRID:AB_2143221
- Product name
- MGMT antibody
- Antibody type
- Polyclonal
- Description
- MGMT antibody (Cat. #17195-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells-derived exosomes.
Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
Exosomal microRNA-222-3p increases UVB sensitivity of lens epithelium cells by suppressing MGMT.
LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing.
Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment.
A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.
GSK3β palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2-STAT3 axis.
CN-3 increases TMZ sensitivity and induces ROS-dependent apoptosis and autophagy in TMZ-resistance glioblastoma.
KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response.
GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
FoxD2-AS1 is a prognostic factor in glioma and promotes temozolomide resistance in a O(6)-methylguanine-DNA methyltransferase-dependent manner.
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
DNA damage triggers tubular endoplasmic reticulum extension to promote apoptosis by facilitating ER-mitochondria signaling.
TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage.
Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells.
Renal cell carcinoma with synchronous ipsilateral urothelial carcinoma of the renal pelvis.
Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors.
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Global and MGMT promoter hypomethylation independently associated with genomic instability of lymphocytes in subjects exposed to high-dose polycyclic aromatic hydrocarbon.
Liu X, Liu L, Wu A, Huang S, Xu Z, Zhang X, Li Z, Li H, Dong J
CNS neuroscience & therapeutics 2024 Feb;30(2):e14599
CNS neuroscience & therapeutics 2024 Feb;30(2):e14599
Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
Liang BB, Wang YH, Huang JJ, Lin S, Mao GC, Zhou ZJ, Yan WJ, Shan CY, Wu HZ, Etcheverry A, He YL, Liu FF, Kang HF, Yin AA, Zhang SQ
CNS neuroscience & therapeutics 2024 Apr;30(4):e14465
CNS neuroscience & therapeutics 2024 Apr;30(4):e14465
Exosomal microRNA-222-3p increases UVB sensitivity of lens epithelium cells by suppressing MGMT.
Luo J, Li P, Kang L, Ji M, Zhou T, Qin B, Zhang J, Guan H
International ophthalmology 2023 May;43(5):1611-1628
International ophthalmology 2023 May;43(5):1611-1628
LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing.
Chen QW, Cai QQ, Yang Y, Dong S, Liu YY, Chen ZY, Kang CL, Qi B, Dong YW, Wu W, Zhuang LP, Shen YH, Meng ZQ, Wu XZ
Clinical and translational medicine 2023 Jan;13(1):e1129
Clinical and translational medicine 2023 Jan;13(1):e1129
Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment.
Li X, Yang C, Luo N, Yang Y, Guo Y, Chen P, Cun B
Cancer biomarkers : section A of Disease markers 2022;34(2):275-284
Cancer biomarkers : section A of Disease markers 2022;34(2):275-284
A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.
Li B, Wang J, Liu F, Li R, Hu W, Etcheverry A, Aubry M, Mosser J, Yin A, Zhang X, Wu Y, Chen K, He Y, Wang L
Journal of oncology 2022;2022:6345160
Journal of oncology 2022;2022:6345160
GSK3β palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2-STAT3 axis.
Zhao C, Yu H, Fan X, Niu W, Fan J, Sun S, Gong M, Zhao B, Fang Z, Chen X
Oncogenesis 2022 May 23;11(1):28
Oncogenesis 2022 May 23;11(1):28
CN-3 increases TMZ sensitivity and induces ROS-dependent apoptosis and autophagy in TMZ-resistance glioblastoma.
Xue YY, Lu YY, Sun GQ, Fang F, Ji YQ, Tang HF, Qiu PC, Cheng G
Journal of biochemical and molecular toxicology 2022 Mar;36(3):e22973
Journal of biochemical and molecular toxicology 2022 Mar;36(3):e22973
KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response.
Yang M, Wang C, Zhou M, Bao L, Wang Y, Kumar A, Xing C, Luo W, Wang Y
Nucleic acids research 2022 Jun 24;50(11):6313-6331
Nucleic acids research 2022 Jun 24;50(11):6313-6331
GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Xu H, Jin J, Chen Y, Wu G, Zhu H, Wang Q, Wang J, Li S, Grigore FN, Ma J, Chen CC, Lan Q, Li M
Oncogene 2022 Jul;41(31):3876-3885
Oncogene 2022 Jul;41(31):3876-3885
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Gao Y, Liu B, Feng L, Sun B, He S, Yang Y, Wu G, E G, Liu C, Gao Y, Zhang E, Zhu B
Frontiers in oncology 2019;9:33
Frontiers in oncology 2019;9:33
FoxD2-AS1 is a prognostic factor in glioma and promotes temozolomide resistance in a O(6)-methylguanine-DNA methyltransferase-dependent manner.
Shangguan W, Lv X, Tian N
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2019 Nov;23(6):475-482
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2019 Nov;23(6):475-482
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA, He YL, Etcheverry A, Liu YH, Aubry M, Barnholtz-Sloan J, Liu BL, Mosser J, Lu ZF, Zhang X
Clinical epigenetics 2019 May 14;11(1):76
Clinical epigenetics 2019 May 14;11(1):76
DNA damage triggers tubular endoplasmic reticulum extension to promote apoptosis by facilitating ER-mitochondria signaling.
Zheng P, Chen Q, Tian X, Qian N, Chai P, Liu B, Hu J, Blackstone C, Zhu D, Teng J, Chen J
Cell research 2018 Aug;28(8):833-854
Cell research 2018 Aug;28(8):833-854
TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage.
Yang F, Zhao N, Wu N
Molecular medicine reports 2017 Sep;16(3):2962-2968
Molecular medicine reports 2017 Sep;16(3):2962-2968
Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells.
Zhang L, Yan Y, Jiang Y, Qian J, Jiang L, Hu G, Lu Y, Luo C
Oncology letters 2017 Oct;14(4):4263-4269
Oncology letters 2017 Oct;14(4):4263-4269
Renal cell carcinoma with synchronous ipsilateral urothelial carcinoma of the renal pelvis.
Lu Q, Zhuang J, Guo H
Oncology letters 2017 Jun;13(6):4521-4525
Oncology letters 2017 Jun;13(6):4521-4525
Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors.
Ambady P, Wu YJ, Walker JM, Kersch C, Pagel MA, Woltjer RL, Fu R, Muldoon LL, Neuwelt EA
Cancer gene therapy 2017 Aug;24(8):348-357
Cancer gene therapy 2017 Aug;24(8):348-357
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Li J, Cai J, Zhao S, Yao K, Sun Y, Li Y, Chen L, Li R, Zhai X, Zhang J, Jiang C
Journal of experimental & clinical cancer research : CR 2016 Nov 28;35(1):184
Journal of experimental & clinical cancer research : CR 2016 Nov 28;35(1):184
Global and MGMT promoter hypomethylation independently associated with genomic instability of lymphocytes in subjects exposed to high-dose polycyclic aromatic hydrocarbon.
Duan H, He Z, Ma J, Zhang B, Sheng Z, Bin P, Cheng J, Niu Y, Dong H, Lin H, Dai Y, Zhu B, Chen W, Xiao Y, Zheng Y
Archives of toxicology 2013 Nov;87(11):2013-2022
Archives of toxicology 2013 Nov;87(11):2013-2022
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Jurkat cells were subjected to SDS PAGE followed by western blot with 17195-1-AP(MGMT antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human kidney using 17195-1-AP(MGMT antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The MGMT antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human MGMT. This antibody recognizes human antigen. The MGMT antibody has been validated for the following applications: ELISA, WB, IHC analysis.
